Emcure Pharmaceuticals Limited

BSE: EMCURE544210ISIN INE168P01015

Healthcare
Pharmaceuticals
BSE 500

Share price

₹2,174.55+192.00 (+9.68%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,180.80
52W low: ₹1,307.50
Off 52W high: -0.29%
1M return: +12.17%
3M return: +11.00%
6M return: +31.00%
1Y return: +64.07%
20D avg volume: 16,335
50 DMA: ₹1,898.74
200 DMA: ₹1,730.51

Key ratios Consolidated

Market cap: ₹41,254 Cr
Current price: ₹2,174.55
52W high / low: ₹2,180.80 / ₹1,307.50
Face value: ₹10.00
P/E: 37.75
P/B: 7.72
EPS (TTM): ₹57.60
Book value / share: ₹281.69
ROE: —
ROCE: 25.10%
Operating margin: —
Net margin: —
Debt / equity: 0.24
Net debt: ₹1,067 Cr
Interest cover: 9.96
Dividend yield: 0.17%
Dividend / share (TTM): ₹3.60
Payout: 6.25%
Cash conversion cycle: 125.0 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	2,820	2,580	2,470	2,363	2,270	2,101	2,116	1,963	2,002	1,815	—
	3.25	2.07	3.99	1.85	3.12	3.70	4.45	3.90	35.65	23.44	—
	2,824	2,583	2,474	2,365	2,273	2,104	2,121	1,967	2,038	1,839	—
	2,378	2,189	2,143	2,013	1,932	1,810	1,850	1,737	1,764	1,631	—
	642.13	481.14	418.58	421.23	420.46	432.50	403.87	399.82	391.49	331.72	—
	625.41	555.12	661.49	560.11	625.17	550.48	571.86	428.93	502.30	380.15	—
	434.71	409.50	386.78	387.33	384.62	393.47	373.37	366.93	355.59	350.40	—
	35.58	31.54	46.40	37.98	32.54	26.75	39.02	31.78	46.22	58.76	—
	109.66	109.50	106.27	104.68	104.64	99.46	96.84	96.81	96.90	93.59	—
	655.55	565.30	600.28	520.98	520.19	488.28	448.37	451.23	476.85	445.32	—
	445.85	393.53	330.88	351.94	341.42	294.26	270.99	229.92	273.41	207.41	—
	0.00	0.00	10.30	-38.15	0.00	-3.50	-10.38	0.00	0.00	0.00	—
	445.85	393.53	341.18	313.79	341.42	290.76	260.61	229.92	273.41	207.41	—
	120.78	101.03	97.44	82.42	90.05	75.97	63.38	73.83	71.86	54.82	—
	325.07	292.49	243.74	231.37	251.37	214.79	197.24	156.09	201.55	152.59	—
	17.16	15.50	12.84	12.16	12.85	10.92	9.97	8.12	10.33	7.95	—
Key metrics
	591.09	534.57	493.85	456.45	478.60	416.97	396.47	358.51	416.53	359.76	—
	21.00%	20.70%	20.00%	19.30%	21.10%	19.90%	18.70%	18.30%	20.80%	19.80%	—
	11.50%	11.30%	9.90%	9.80%	11.10%	10.20%	9.30%	8.00%	10.10%	8.40%	—
	7.60%	—	6.80%	—	6.60%	—	5.40%	—	—	—	—
	24.30%	22.80%	16.70%	20.40%	13.40%	15.70%	—	—	—	—	—
	29.30%	36.20%	23.60%	48.20%	24.70%	40.80%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	10,234	9,204	7,896	—
	11.16	12.66	67.26	—
	10,245	9,216	7,963	—
	8,723	7,898	6,982	—
	1,963	1,693	1,527	—
	2,402	2,397	1,883	—
	1,618	1,552	1,446	—
	151.50	143.67	175.78	—
	430.11	415.05	384.13	—
	2,342	2,130	1,829	—
	1,522	1,318	981.73	—
	-27.85	-31.35	-10.38	—
	1,494	1,287	971.35	—
	401.67	345.87	263.88	—
	1,093	941.27	707.47	—
	57.66	48.77	36.43	—
Key metrics
	2,076	1,846	1,531	—
	20.28%	20.10%	19.40%	—
	10.68%	10.20%	9.00%	—
	—	25.10%	20.60%	—
	21.12%	16.60%	—	—
	33.34%	33.00%	—	—
	—	582.98	629.94	—
	—	1.00	1.20	—
	—	0.24	0.16	—
	—	1,067	576.17	—
	—	125.0	113.5	—
Balance sheet
	—	9,612	8,233	—
	—	5,709	4,650	—
	—	136.66	155.54	—
	—	2,563	2,002	—
	—	2,398	1,932	—
	—	435.31	327.95	—
	—	1,960	1,954	—
	—	1,808	1,480	—
	—	3,912	2,668	—
	—	1,204	731.71	—
	—	951.87	541.77	—
	—	252.21	189.94	—
	—	4,977	4,642	—
Cash flow
	—	943.54	851.71	—
	—	-1,193	-94.00	—
	—	343.43	-813.96	—
	—	360.56	221.77	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	1,668	1,451	1,468	1,418	1,261	1,097	1,278	1,029	1,105	970.29	—
	33.54	25.03	26.94	138.30	22.75	21.52	22.40	19.41	54.93	32.51	—
	1,702	1,476	1,495	1,557	1,283	1,118	1,301	1,048	1,160	1,003	—
	1,369	1,207	1,196	1,213	1,125	948.93	1,115	980.97	1,040	947.75	—
	530.09	419.71	377.85	368.53	374.18	354.63	365.01	350.91	325.99	266.07	—
	272.37	250.38	253.40	221.14	259.86	160.18	259.83	175.31	232.11	158.46	—
	231.48	210.40	202.37	205.65	202.68	210.42	198.16	196.01	191.12	195.09	—
	32.42	32.78	36.87	33.15	27.71	20.54	24.07	19.93	31.40	37.57	—
	65.01	63.17	63.04	62.14	61.74	59.82	56.91	56.65	56.34	55.08	—
	343.27	267.67	245.00	296.77	266.76	249.97	227.41	236.97	256.56	243.91	—
	332.38	268.67	298.69	343.51	157.89	169.17	186.05	67.25	119.36	55.05	—
	0.00	0.00	7.58	-29.15	0.00	-3.50	0.00	—	—	—	—
	332.38	268.67	306.27	314.37	157.89	165.67	186.05	67.25	119.36	55.05	—
	83.95	68.56	72.57	55.51	40.27	42.88	46.49	17.05	32.44	14.60	—
	248.43	200.11	233.70	258.85	117.62	122.79	139.56	50.20	86.92	40.45	—
	13.10	10.55	12.33	13.65	6.21	6.48	7.37	2.65	4.62	2.23	—
Key metrics
	429.81	364.62	406.18	409.66	247.34	246.03	267.03	143.83	207.10	147.70	—
	25.80%	25.10%	27.70%	28.90%	19.60%	22.40%	20.90%	14.00%	18.70%	15.20%	—
	14.90%	13.80%	15.90%	18.30%	9.30%	11.20%	10.90%	4.90%	7.90%	4.20%	—
	7.20%	—	7.40%	—	4.40%	—	5.70%	—	—	—	—
	32.30%	32.30%	14.80%	37.90%	14.10%	13.00%	—	—	—	—	—
	111.20%	63.00%	67.50%	415.60%	35.30%	203.60%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	6,005	5,243	4,382	—
	223.81	209.52	118.81	—
	6,229	5,453	4,501	—
	4,985	4,483	4,073	—
	1,696	1,475	1,308	—
	997.29	894.58	825.70	—
	849.90	821.12	782.31	—
	135.22	118.27	112.96	—
	253.36	246.73	224.97	—
	1,153	1,058	945.37	—
	1,243	969.26	427.71	—
	-21.57	-25.07	0.00	—
	1,222	944.19	427.71	—
	280.59	211.23	110.58	—
	941.09	732.96	317.13	—
	49.63	38.67	16.95	—
Key metrics
	1,610	1,309	765.64	—
	26.82%	25.00%	17.50%	—
	15.67%	14.00%	7.20%	—
	—	22.90%	14.60%	—
	28.75%	19.70%	—	—
	118.77%	131.10%	—	—
	—	188.39	362.13	—
	—	0.58	1.76	—
	—	0.37	0.22	—
	—	1,355	647.33	—
	—	111.4	92.4	—
Balance sheet
	—	6,914	5,416	—
	—	3,041	2,507	—
	—	11.24	8.49	—
	—	1,535	1,191	—
	—	1,207	1,038	—
	—	179.63	137.82	—
	—	1,445	1,460	—
	—	1,140	1,120	—
	—	2,267	1,719	—
	—	1,366	655.82	—
	—	701.43	249.53	—
	—	664.84	406.29	—
	—	3,711	3,024	—
Cash flow
	—	423.56	558.28	—
	—	-948.10	-435.61	—
	—	525.76	-49.25	—
	—	235.17	196.15	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +28.75%
Profit YoY (TTM): +118.77%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +21.12%
Profit YoY (TTM): +33.34%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 77.82%

Quarter	September 2026	June 2026
Promoter %	77.82%	77.83%

Holder	Type	Holding	Previous	Change
Satish R Mehta	Promoter	39.74%	39.75%	-0.01%
Everest Trust (Shares held by Sanjay Rajanikant Mehta with Sonali Sanjay Mehta, as trustees)	Promoter Group	7.65%	7.65%	0.00%
Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as trustees)	Promoter Group	7.65%	7.65%	0.00%
Samit Satish Mehta	Promoter	7.14%	7.14%	0.00%
Bhavana Satish Mehta	Promoter Group	4.70%	4.70%	0.00%
Namita Vikas Thapar	Promoter	2.67%	2.67%	0.00%
Kotak Midcap Fund	Public	2.31%	1.93%	+0.38%
Pushpa Rajnikant Mehta	Promoter Group	2.05%	2.05%	0.00%
Sanjay Rajanikant Mehta	Promoter Group	1.95%	1.95%	0.00%
Sunil Rajanikant Mehta	Promoter	1.50%	1.50%	0.00%
Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Elss Tax Saver Fund	Public	1.45%	—	—
Nippon Life India Trustee Ltd-A/C Nippon India Multi Cap Fund	Public	1.19%	1.33%	-0.14%
Government Pension Fund Global	Public	1.05%	1.05%	0.00%
Kamini Sunil Mehta	Promoter Group	0.88%	0.88%	0.00%
Niraj Sunil Mehta	Promoter Group	0.55%	0.58%	-0.03%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Audio recording of Earnings Call - Q2 FY273 Nov 2026 · Company Update / Analyst / Investor Meet
Presentation on Unaudited Financial Results for the quarter ended September 30, 20263 Nov 2026 · Company Update / Investor Presentation
Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 20263 Nov 2026 · Result / Financial Results
For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026.3 Nov 2026 · Board Meeting / Outcome of Board Meeting
Intimation for Earnings Call - Q2 FY2714 Oct 2026 · Company Update / Analyst / Investor Meet
Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial ....14 Oct 2026 · Board Meeting / Board Meeting
Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 202612 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited - Holding ....12 Oct 2026 · Company Update / Scheme of Arrangement
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order(s)2 Oct 2026 · Company Update / Award of Order / Receipt of Order
Intimation of Closure of Trading Window29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation25 Sep 2026 · Company Update / Investor Presentation
Change in composition of the Board of the Company23 Sep 2026 · Company Update / General
Voting Results of the 45th Annual General Meeting of the Company along with the consolidated Report of the Scrutinizer23 Sep 2026 · AGM/EGM / AGM
Proceedings of the 45th Annual General Meeting of the Members of the Company21 Sep 2026 · AGM/EGM / AGM
Allotment of 11,400 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 201311 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Dispatch of letter to the members whose e-mail addresses are not registered with the Company/Depository Participants1 Sep 2026 · Company Update / General
Intimation of schedule of Investor Meet on Friday, September 04, 20261 Sep 2026 · Company Update / Analyst / Investor Meet
Reaffirmation of Credit Ratings by CARE Ratings Limited1 Sep 2026 · Company Update / Credit Rating
Newspaper Advertisement of Notice of the 45th Annual General Meeting and e-voting information29 Aug 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Report for the Financial Year 2025-2628 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of the 45th Annual General Meeting of Emcure Pharmaceuticals Limited28 Aug 2026 · AGM/EGM / AGM
Annual Report of the Company for the Financial Year 2025-2628 Aug 2026 · Others / Reg. 34 (1) Annual Report
Allotment of 19,100 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 201325 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Transcript of Earnings Call - Q1 FY2712 Aug 2026 · Company Update / Analyst / Investor Meet
Update on USFDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, India8 Aug 2026 · Company Update / General
Analyst/ Investor Meet on Tuesday, September 22, 20267 Aug 2026 · Company Update / Analyst / Investor Meet
Analyst/ Investor Meet on Thursday, September 17, 20267 Aug 2026 · Company Update / Analyst / Investor Meet
Analyst/ Investor Meet on Tuesday, September 01, 20267 Aug 2026 · Company Update / Analyst / Investor Meet
Analyst/ Investor Meet on Tuesday, August 18, 20267 Aug 2026 · Company Update / Analyst / Investor Meet
Analyst/Investor Meet on Wednesday, August 12, 20267 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 20267 Aug 2026 · Company Update / Newspaper Publication
Audio recording of Earnings Call - Q1 FY276 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of date of the 45th Annual General Meeting and Record Date for payment of Final Dividend on Equity Shares for the Financial Year March 31, 20266 Aug 2026 · Corp. Action / Record Date
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Change in composition of the Board of the Company6 Aug 2026 · Company Update / Change in Management
Presentation on Unaudited Financial Results for the quarter ended June 30, 20266 Aug 2026 · Company Update / Investor Presentation
Unaudited Financial Results (Standalone and consolidated) for the quarter ended June 30, 20266 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on August 06, 20266 Aug 2026 · Board Meeting / Outcome of Board Meeting
Update on completion of acquisition of shares of Gennova Biopharmaceuticals Limited22 Jul 2026 · Company Update / General
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Completion of 2nd term of Independent Director21 Jul 2026 · Company Update / Change in Management
Press Release titled "Emcure to Expand the Use of Poviztra for MASH Indication Following CDSCO Approval".20 Jul 2026 · Company Update / Press Release / Media Release

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 3.6000	4 Sep 2026	4 Sep 2026	—
Final Dividend - Rs. - 3.0000	14 Aug 2025	14 Aug 2025	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results